Abstract 2756
Background
Malign obstructive jaundice (MOJ) in cancer is due to liver metastasis and/or biliary duct compression. Percutaneous biliary drainage (PBD) is a palliative procedure. Prognostic & predictive factors are needed for selection of the cancer patients who will get more benefit from PBD in MOJ. We evaluated cancer patients (CP) who had PBD for MOJ for clinicopathological features (CPF) & survival outcomes besides potential predictive markers for PBD.
Methods
110 CP who had PBD for MOJ between 2010 & 2016 were evaluated retrospectively. The correlation between biochemical values, CPF (extrahepatic metastasis (EM), obstruction cause (OC), stent localization) & total bilirubin (TB) was evaluated by ROC analysis. The CP were analyzed according to TB after PBD [groups A: normal (1 mg/dl or 20% decrease), C: stable/increase.
Results
Median age was 60 (28-82) years. 57 were male. In univariate analysis, EM & OC were significant factors with concordance to biochemical values. Albumin (p = 0.007, OR: 5.2, 1,5-17,1), LDH (p = 0.041, OR:2.5, 1.02-6,2) & OC (p = 0.019, OR:3.4, 1.2-9,9) remained significant in multivariate analysis. The CP were grouped according to these risk factors (RF): groups 1 (22,7%: no RF), 2 (64,5%: 1-2 RF), 3 (12,7%: >3 RF). TB normalization & OS after PBD are shown in table 1. Stenting proximal to choledoc had better TB normalization (44,7% vs 17,6%, p = 0.006).Chemotherapy rates were as 60% for group A, 36,8% for group B & 21,9% for group C (p = 0.004). 6-months OS was 41,3% for patients receiving chemotherapy & 17,7% for others (p
Conclusions
| Group A* (%) | Group A* (%) OS | |
|---|---|---|
| Total bilirubin (mg/dl) | ||
| >13 | 19,6 | 18,5 |
| 2,5 | 12,1 | 6 |
Clinical trial identificationLegal entity responsible for the studyN/A FundingN/A DisclosureAll authors have declared no conflicts of interest. Resources from the same session2354 - The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institutionPresenter: Seung Tae Kim Session: Poster Display Resources: Abstract 2594 - Neuroendocrine carcinomas of the colorectal origin - Polish experiencePresenter: Agnieszka Kolasińska-Ćwikła Session: Poster Display Resources: Abstract 2539 - Neuroendocrine neoplasms of the appendix including goblet cell carcinoidsPresenter: Agnieszka Kolasinska-Cwikla Session: Poster Display Resources: Abstract 1245 - Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendixPresenter: Amir Mehrvarz Sarshekeh Session: Poster Display Resources: Abstract 3902 - Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET)Presenter: Riccardo Marconcini Session: Poster Display Resources: Abstract 3882 - Differential clinical and pathological characteristics of hereditary neuroendocrine pancreatic tumours (NEPT)Presenter: Gema Marín Zafra Session: Poster Display Resources: Abstract 2296 - Natural course of thyroid cancer nodules compared with benign thyroid nodulesPresenter: Kyung-Jin Yun Session: Poster Display Resources: Abstract 4083 - Reassessment of proliferative activity at disease progression in neuroendocrine neoplasmsPresenter: Noemi Cicchese Session: Poster Display Resources: Abstract 3866 - 18F-FDG-PET to predict disease progression in advanced digestive neuroendocrine neoplasmsPresenter: Maria Rinzivillo Session: Poster Display Resources: Abstract 3651 - UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE studyPresenter: John Ramage Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|